Results per Page:
Osteoporosis drug may reduce breast cancer risk
Andrea LaCroix and colleagues tie lasofoxifene to 79 percent lowered overall risk of breast cancer in postmenopausal women
Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer
Hutchinson Center Participated in Clinical Trial
A Call to Action — Women Across the State Needed for Breast Cancer Study Looking at Preventive Benefits of Tamoxifen and Raloxifene
Fred Hutchinson Cancer Research Center and its five satellite sites hope to recruit 200 women to the study over the next three years
STAR Enrolls 6,139 Women in First Year; 16,000 More Women at Increased Risk of Breast Cancer Sought
Six thousand in, sixteen thousand to go.
Major Breast Cancer Prevention Trial Seeks Minority Women During
National Minority Cancer Awareness Week Five Sites in Washington and Oregon Hope to Recruit More Women To the Study of Tamoxifen and Raloxifene, known as STAR